Atezolizumab plus Tiraglolumab

Phase 2

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

RHHBYPhase 2$316.4B

Atezolizumab plus Tiraglolumab Phase 2 Est. Readout

Atezolizumab plus Tiraglolumab• Squamous Cell Carcinoma of the Anal Canal45

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Squamous Cell Carcinoma of the Anal Canal

View Full Landscape

Drug Information

Target Indication

Squamous Cell Carcinoma of the Anal Canal

Clinical Trial

NCT05661188

Last updated: 8/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts